Cover Image
市場調查報告書

PharmaPoint:重度憂鬱症 (MDD) - 全球醫藥品的預測與市場分析

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

出版商 GlobalData 商品編碼 314723
出版日期 內容資訊 英文 392 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:重度憂鬱症 (MDD) - 全球醫藥品的預測與市場分析 PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025
出版日期: 2016年10月05日 內容資訊: 英文 392 Pages
簡介

重度憂鬱症 (MDD) ,是全球是最常見的精神疾病之一。MDD市場競爭激烈,有30項以上的上市產品可用於MDD患者的治療。主要產品 (Eli Lilly的Cymbalta,大塚製藥/BMS的Abilify)的專利期間的屆滿,抗憂鬱藥的新產品 (Lundbeck/武田藥品工業的Brintellix) 和有未來潛力的後期階段的開發中產品的引進將近,市場有大動作。

本報告提供重度憂鬱症 (MDD) 治療藥市場相關調查分析,疾病的概要與指南,競爭情形,主要藥物的詳細資訊 (產品說明,安全性,有效性) 、SWOT分析,銷售額預測,影響分析 (趨勢,推動因素、阻礙因素) 等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因、病理生理學
    • 病因
    • 病理生理學
  • 分類
  • 症狀和亞型
  • 預後
  • QOL

第4章 流行病學

  • 疾病的背景
  • 危險因素和合併症
  • 全球趨勢
  • 預測手法
    • 利用之資訊來源
    • 預測的前提條件與手法
    • 未利用之資訊來源
  • MDD的流行病學預測
    • 12個月的整體患者數
    • 12個月的整體患者數 (各年齡)
    • 12個月的整體患者數 (性別)
    • 12個月的整體患者數 (年齡調整)
    • 12個月的整體患者數:各重症度
  • 議論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第5章 疾病的管理

  • 診斷和治療概要
  • 美國
  • EU5個國家
  • 日本

第6章 競爭評估

  • 概要
  • 選擇性血清素回收抑制劑
  • 血清素-正腎上腺素再回收抑制劑
  • 多樣的抗憂鬱藥
  • 其他抗憂鬱藥
  • 抗精神病藥
  • 其他的治療藥物類型

第7章 未滿足需求和機會

  • 概要
  • 具有效性的新治療方法
  • 安全性的提高
  • 快速作用
  • 個體化治療的方法
  • 患者的治療結果預測的管理

第8章 開發平台評估

  • 概要
  • 臨床實驗製圖
  • 臨床開發中的潛力藥物
  • 初期階段開發中的有潛力的藥劑
  • 其他開發中的藥物

第9章 現在、未來的主要企業

  • 概要
  • 企業策略趨勢
  • 企業簡介

第10章 市場預測

  • 全球市場
  • 美國
  • EU5個國家
  • 日本

第11章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC126PIDR

Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized by single or recurrent major depressive episodes (MDEs), where patients can typically experience periods of depressed mood, loss of energy, abnormal cognition, anxiety and suicidal ideation. Similar to other neuropsychiatric disorders, MDD has a multifaceted and varied etiology, and remains poorly understood. The MDD market is crowded and competitive, with more than 30 products available for the treatment of patients, the majority of which are now available as inexpensive generics. The MDD market is therefore in a dynamic phase where patent expiries for historically top-selling products such as Eli Lilly's Cymbalta and Otsuka/BMS' Abilify have occurred, and recent launches of Lundbeck/Takeda's Trintellix and Otsuka/Lundbeck's Rexulti will be a significant driver of growth in the 7MM. Growth in the MDD market is also expected to be driven by the potential introduction of six promising late-stage pipeline products into the market during the forecast period, all of which are directed towards treatment-resistant patients, a significant unmet need.

Highlights

Key Questions Answered

  • The MDD market is widely genericized. In light of this, what are the current clinical and environmental unmet needs? Will there be opportunities in this market for drug developers throughout the forecast period?
  • There are five substantial unmet needs that exist in the MDD market. Will pipeline drugs fulfil any of the unmet needs for MDD? Which unmet needs will continue to provide opportunity for drug developers during the forecast period?
  • Six late-stage pipeline products are expected to launch during the forecast period to 2025. What impact will these drugs have on the market? How will they affect the treatment algorithm for MDD?

Key Findings

  • The main drivers of growth in the MDD market will be the uptake of atypical antipsychotic products throughout the 7MM, most notably from Otsuka/Lundbeck's Rexulti. These agents are forecast to be the highest selling MDD products by 2025, accounting for 38.9% of the MDD market in the 7MM.
  • The six late-stage pipeline products are all adjunctive therapies aimed at treating treatment-resistant patients and aim to satisfy major unmet needs within the MDD market; providing therapies with better efficacy, improved safety profiles, and rapid onsets of action.
  • The biggest barrier for growth in the MDD market will be fierce competition from generic products. This limits market opportunities for new and existing players, as uptake of novel pipeline products would be hindered by their premium price point.
  • Growth in the MDD market is also expected to be driven by increasing diagnosed prevalence of MDD, due to increased public awareness and routine screening for depressive disorders, as well as an increase in socioeconomic stress.

Scope

  • Overview of MDD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized MDD market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.
  • Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the MDD therapeutics market.
  • Pipeline analysis: focus on eight late-stage pipeline MDD drugs, discussing emerging trends as well as an overview of earlier phase drugs.
  • Analysis of the current and future market competition in the global MDD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global MDD therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global MDD therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global MDD therapeutics market from 2015-2025.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

1 Table of Contents 10

  • 1.1 List of Tables 15
  • 1.2 List of Figures 20

2 Introduction 22

  • 2.1 Related Reports 22
  • 2.2 Upcoming Related Reports 23

3 Disease Overview 24

  • 3.1 Etiology and Pathophysiology 24
    • 3.1.1 Etiology 24
    • 3.1.2 Pathophysiology 25
  • 3.2 Classification 28
  • 3.3 Symptoms and Subtypes of Major Depressive Disorder 30
  • 3.4 Prognosis 31
  • 3.5 Quality of Life 31

4 Epidemiology 32

  • 4.1 Disease Background 32
  • 4.2 Risk Factors and Comorbidities 33
  • 4.3 Global Trends 35
  • 4.4 Forecast Methodology 38
    • 4.4.1 Sources Used Tables 38
    • 4.4.2 Forecast Assumptions and Methods 40
    • 4.4.3 Sources Not Used 44
  • 4.5 Epidemiological Forecast for MDD (2015-2025) 46
    • 4.5.1 12-Month Total Prevalent Cases of MDD 46
    • 4.5.2 Age-Specific 12-Month Total Prevalent Cases of MDD 48
    • 4.5.3 Sex-Specific 12-Month Total Prevalent Cases of MDD 49
    • 4.5.4 Age-Standardized 12-Month Total Prevalence of MDD 51
    • 4.5.5 12-Month Total Prevalent Cases of MDD by Severity 52
  • 4.6 Discussion 53
    • 4.6.1 Epidemiological Forecast Insight 53
    • 4.6.2 Limitations of the Analysis 54
    • 4.6.3 Strengths of the Analysis 55

5 Disease Management 56

  • 5.1 Diagnosis and Treatment Overview 56
    • 5.1.1 Diagnosis 56
    • 5.1.2 Treatment Guidelines 57
    • 5.1.3 Clinical Practice 59
  • 5.2 US 63
  • 5.3 5EU 66
  • 5.4 Japan 70

6 Competitive Assessment 73

  • 6.1 Overview 73
  • 6.2 Selective Serotonin Reuptake Inhibitors 75
    • 6.2.1 Lexapro (Escitalopram) 75
    • 6.2.2 Viibryd (Vilazodone) 83
    • 6.2.3 Other Selective Serotonin Reuptake Inhibitors 87
  • 6.3 Serotonin-Norepinephrine Reuptake Inhibitors 101
    • 6.3.1 Cymbalta (Duloxetine) 101
    • 6.3.2 Effexor (Venlafaxine) 109
    • 6.3.3 Fetzima (Levomilnacipran) 116
    • 6.3.4 Savella (Milnacipran) 122
    • 6.3.5 Pristiq (Desvenlafaxine) 127
  • 6.4 Multimodal Antidepressants 132
    • 6.4.1 Trintellix (Vortioxetine) 132
  • 6.5 Other Antidepressants 141
    • 6.5.1 Bupropion 141
    • 6.5.2 Symbyax (Olanzapine/Fluoxetine) 147
    • 6.5.3 Mirtazapine 152
    • 6.5.4 Monoamine Oxidase Inhibitors 157
    • 6.5.5 Tricyclic Antidepressants 161
  • 6.6 Antipsychotics 165
    • 6.6.1 Abilify (Aripiprazole) 165
    • 6.6.2 Seroquel XR (Quetiapine XR) 172
    • 6.6.3 Rexulti (Brexpiprazole) 177
  • 6.7 Other Therapeutic Classes 183

7 Unmet Need and Opportunity 184

  • 7.1 Overview 184
  • 7.2 New Therapies with Better Efficacy 186
    • 7.2.1 Unmet Need 186
    • 7.2.2 Gap Analysis 188
    • 7.2.3 Opportunity 189
  • 7.3 Improved Safety Profiles 190
    • 7.3.1 Unmet Need 190
    • 7.3.2 Gap Analysis 192
    • 7.3.3 Opportunity 193
  • 7.4 Rapid Onset of Action 195
    • 7.4.1 Unmet Need 195
    • 7.4.2 Gap Analysis 196
    • 7.4.3 Opportunity 198
  • 7.5 Personalized Treatment Approach 199
    • 7.5.1 Unmet Need 199
    • 7.5.2 Gap Analysis 200
    • 7.5.3 Opportunity 201
  • 7.6 Manage Patient Outcome Expectations 203
    • 7.6.1 Unmet Need 203
    • 7.6.2 Gap Analysis 205
    • 7.6.3 Opportunity 206

8 Pipeline Assessment 208

  • 8.1 Overview 208
  • 8.2 Clinical Trial Mapping 208
    • 8.2.1 Clinical Trials by Class of Therapy 208
  • 8.3 Promising Drugs in Clinical Development 209
    • 8.3.1 ALKS-5461 213
    • 8.3.2 Vraylar (Cariprazine) 222
    • 8.3.3 ASC-01 229
    • 8.3.4 AXS-05 232
    • 8.3.5 Esketamine 239
    • 8.3.6 Rapastinel (GLYX-13) 247
    • 8.3.7 Strada (MSI-195) 255
    • 8.3.8 Viotra (Tramadol) 261
  • 8.4 Promising Drugs in Early-Stage Development 268
    • 8.4.1 CGP3466B 268
    • 8.4.2 NSI-189 269
  • 8.5 Other Drugs in Development 270

9 Current and Future Players 272

  • 9.1 Overview 272
  • 9.2 Trends in Corporate Strategy 274
  • 9.3 Company Profiles 275
    • 9.3.1 Allergan 275
    • 9.3.2 e-Therapeutics 278
    • 9.3.3 Alkermes 280
    • 9.3.4 Pfizer 282
    • 9.3.5 Otsuka 284
    • 9.3.6 Janssen 287
    • 9.3.7 Eli Lilly 290
    • 9.3.8 Lundbeck 292
    • 9.3.9 Takeda 295
    • 9.3.10 Axsome Therapeutics 297

10 Market Outlook 299

  • 10.1 Global Markets 299
    • 10.1.1 Forecast 299
    • 10.1.2 Drivers and Barriers - Global Issues 306
  • 10.2 US 306
    • 10.2.1 Forecast 306
    • 10.2.2 Key Events 309
    • 10.2.3 Drivers and Barriers 310
  • 10.3 5EU 310
    • 10.3.1 Forecast 310
    • 10.3.2 Key Events 315
    • 10.3.3 Drivers and Barriers 316
  • 10.4 Japan 318
    • 10.4.1 Forecast 318
    • 10.4.2 Key Events 320
    • 10.4.3 Drivers and Barriers 321

11 Appendix 322

  • 11.1 Bibliography 322
  • 11.2 Abbreviations 365
  • 11.3 Methodology 371
  • 11.4 Forecasting Methodology 371
    • 11.4.1 Diagnosed MDD Patients 371
    • 11.4.2 Percent Drug-Treated Patients 372
    • 11.4.3 Percent Treatment-Resistant Patients 372
    • 11.4.4 Drugs Included in Each Therapeutic Class 372
    • 11.4.5 Key Launch Dates and Patent Expiries 373
    • 11.4.6 General Pricing Assumptions 373
    • 11.4.7 Individual Drug Assumptions 374
    • 11.4.8 Generic Erosion 384
    • 11.4.9 Pricing of Pipeline Agents 385
  • 11.5 Primary Research - KOLs Interviewed for this Report 386
  • 11.6 Primary Research - High-Prescriber Survey 388
  • 11.7 About the Authors 389
    • 11.7.1 Analysts 389
    • 11.7.2 Therapy Area Director 389
    • 11.7.3 Epidemiologist 390
    • 11.7.4 Global Director of Therapy Analysis and Epidemiology 390
  • 11.8 About GlobalData 391
  • 11.9 Disclaimer 391

List of Tables

  • Table 1: Classification and Criteria of MDD (DSM-IV) and MDE (ICD-10) 29
  • Table 2: Subtypes of Major Depressive Disorder 30
  • Table 3: DSM-IV Diagnostic Criteria for MDD 33
  • Table 4: Risk Factors and Comorbidities for MDD 34
  • Table 5: Prevalence of the Most Frequent Psychiatric Comorbidities in Individuals With and Without MDD, Ages 18-64 Years 35
  • Table 6: 7MM, Total Prevalence (%) of MDD According to the DSM-IV Criteria, ≥18 Years 37
  • Table 7: 7MM, Total Prevalence (%) of MDD According to the DSM-III Criteria 37
  • Table 8: 7MM, Sources Used to Forecast the 12-Month Total Prevalence of MDD 39
  • Table 9: Sources Used to Forecast the 12-Month Total Prevalent Cases of MDD by Severity 40
  • Table 10: 7MM, Sources Not Used in Epidemiological Forecast for the 12-Month Total Prevalent Cases of MDD 45
  • Table 11: 7MM, 12-Month Total Prevalent Cases of MDD, Ages ≥18 Years, Both Sexes, N, Selected Years 2015-2025 47
  • Table 12: 7MM, 12-Month Total Prevalent Cases of MDD, by Age, Both Sexes, N (Row %), 2015 48
  • Table 13: 7MM, 12-Month Total Prevalent Cases of MDD, by Sex, Ages ≥18 Years, N (Row %), 2015 50
  • Table 14: Severity of Depressive Episodes According to ICD-10 and DSM-IV Diagnostic Criteria 57
  • Table 15: Treatment Guidelines for Major Depressive Disorder 58
  • Table 16: Most-Prescribed Drugs for MDD by Class in the 7MM, 2015 59
  • Table 17: Country Profile - US 66
  • Table 18: Country Profile - 5EU 69
  • Table 19: Country Profile - Japan 72
  • Table 20: Leading Treatments for MDD, 2016 75
  • Table 21: Product Profile - Lexapro 79
  • Table 22: Lexapro/Cipralex SWOT Analysis, 2016 82
  • Table 23: Product Profile - Viibryd 85
  • Table 24: Summary of Efficacy Results for the Primary Endpoint in Viibryd Clinical Trials 86
  • Table 25: Viibryd SWOT Analysis, 2016 87
  • Table 26: Summary of SSRIs, 2016 91
  • Table 27: SSRIs SWOT Analysis, 2016 101
  • Table 28: Product Profile - Cymbalta 106
  • Table 29: Cymbalta SWOT Analysis, 2016 108
  • Table 30: Product Profile - Effexor 113
  • Table 31: Effexor SWOT Analysis, 2016 115
  • Table 32: Product Profile - Fetzima 119
  • Table 33: Fetzima SWOT Analysis, 2016 121
  • Table 34: Product Profile - Savella 124
  • Table 35: Savella SWOT Analysis, 2016 126
  • Table 36: Product Profile - Pristiq 129
  • Table 37: Pristiq SWOT Analysis, 2016 131
  • Table 38: Product Profile - Trintellix 138
  • Table 39: Trintellix SWOT Analysis, 2016 140
  • Table 40: Product Profile - Bupropion 144
  • Table 41: Bupropion SWOT Analysis, 2016 146
  • Table 42: Product Profile - Symbyax 149
  • Table 43: Symbyax SWOT Analysis, 2016 151
  • Table 44: Product Profile - Mirtazapine 155
  • Table 45: Mirtazapine SWOT Analysis, 2016 157
  • Table 46: MAOIs SWOT Analysis, 2016 161
  • Table 47: TCAs SWOT Analysis, 2016 165
  • Table 48: Product Profile - Abilify 169
  • Table 49: Abilify SWOT Analysis, 2016 171
  • Table 50: Product Profile - Seroquel XR 174
  • Table 51: Seroquel XR SWOT Analysis, 2016 176
  • Table 52: Product Profile - Rexulti 180
  • Table 53: Rexulti SWOT Analysis, 2016 182
  • Table 54: Summary of Minor Therapeutic Classes in MDD, 2016 183
  • Table 55: Unmet Needs and Opportunities in MDD 185
  • Table 56: Promising Drugs in Clinical Development for MDD, 2016 210
  • Table 57: Comparison of Drugs in Development for MDD, 2016 212
  • Table 58: Product Profile - ALKS-5461 217
  • Table 59: SWOT Analysis - ALKS-5461, 2016 221
  • Table 60: Product Profile - Vraylar 225
  • Table 61: SWOT Analysis - Vraylar, 2016 228
  • Table 62: Product Profile - ASC-01 230
  • Table 63: SWOT Analysis - ASC-01, 2016 232
  • Table 64: Product Profile - AXS-05 236
  • Table 65: SWOT Analysis - AXS-05, 2016 238
  • Table 66: Product Profile - Esketamine 243
  • Table 67: SWOT Analysis - Esketamine, 2016 246
  • Table 68: Product Profile - Rapastinel 251
  • Table 69: SWOT Analysis - Rapastinel, 2016 254
  • Table 70: Product Profile - Strada 259
  • Table 71: SWOT Analysis - Strada, 2016 261
  • Table 72: Product Profile - Viotra 264
  • Table 73: SWOT Analysis - Viotra, 2015 267
  • Table 74: Drugs in Development, 2016 271
  • Table 75: Key Companies in the MDD Market in the 7MM 273
  • Table 76: Allergan's MDD Portfolio Assessment, 2016 277
  • Table 77: Allergan SWOT Analysis in MDD, 2015-2025 278
  • Table 78: e-Therapeutics' MDD Portfolio Assessment, 2016 279
  • Table 79: e-Therapeutics SWOT Analysis in MDD, 2015-2025 280
  • Table 80: Alkermes' MDD Portfolio Assessment, 2016 282
  • Table 81: Alkermes SWOT Analysis in MDD, 2015-2025 282
  • Table 82: Pfizer's MDD Portfolio Assessment, 2016 283
  • Table 83: Pfizer SWOT Analysis in MDD, 2015-2025 284
  • Table 84: Otsuka's MDD Portfolio Assessment, 2016 286
  • Table 85: Otsuka SWOT Analysis in MDD, 2015-2025 287
  • Table 86: Janssen's MDD Portfolio Assessment, 2016 289
  • Table 87: Janssen SWOT Analysis in MDD, 2015-2025 290
  • Table 88: Eli Lilly's MDD Portfolio Assessment, 2016 291
  • Table 89: Eli Lilly SWOT Analysis in MDD, 2015-2025 292
  • Table 90: Lundbeck's MDD Portfolio Assessment, 2016 294
  • Table 91: Lundbeck SWOT Analysis in MDD, 2015-2025 295
  • Table 92: Takeda's MDD Portfolio Assessment, 2016 296
  • Table 93: Takeda SWOT Analysis in MDD, 2015-2025 296
  • Table 94: Axsome Therapeutics' MDD Portfolio Assessment, 2016 298
  • Table 95: Axsome Therapeutics SWOT Analysis in MDD, 2015-2025 298
  • Table 96: MDD Market - Drivers and Barriers, 2015-2025 306
  • Table 97: Key Events Impacting Sales for MDD Therapies in the US, 2015-2025 309
  • Table 98: MDD Market - Drivers and Barriers in the US, 2015-2025 310
  • Table 99: Key Events Impacting Sales for MDD Therapies in the 5EU, 2015-2025 315
  • Table 100: MDD Market - Drivers and Barriers in the 5EU, 2015-2025 316
  • Table 101: National Healthcare Authorities and Governmental Drug Pricing Authorities in the 5EU 317
  • Table 102: Key Events Impacting Sales for MDD Therapies in Japan, 2015-2025 320
  • Table 103: MDD Market - Drivers and Barriers in Japan, 2015-2025 321
  • Table 104: Key Launch Dates 373
  • Table 105: Key Patent Expiries 373
  • Table 106: High-Prescribing Physicians (Non-KOLs) Surveyed, by Country 388

List of Figures

  • Figure 1: Overview of Targets of Antidepressant Action on Noradrenergic and Serotonergic Neurons 28
  • Figure 2: 7MM, 12-Month Total Prevalent Cases of MDD, Ages ≥18 Years, Both Sexes, N, 2015-2025 47
  • Figure 3: 7MM, 12-Month Total Prevalent Cases of MDD, by Age, Both Sexes, N, 2015 49
  • Figure 4: 7MM, 12-Month Total Prevalent Cases of MDD, by Sex, Ages ≥18 Years, N, 2015 51
  • Figure 5: 7MM, Age-Standardized 12-Month Total Prevalence (%) of MDD, by Sex, Ages ≥18 Years, 2015 52
  • Figure 6: 7MM, 12-Month Total Prevalent Cases of MDD by Severity, Both Sexes, Ages ≥18 Years, 2015 53
  • Figure 7: Disease Management Model for Major Depressive Disorder 60
  • Figure 8: Major Depressive Disorder Treatment Algorithm 62
  • Figure 9: MDD Therapeutics - Phase II and III Clinical Trials in the 7MM, 2016 209
  • Figure 10: MDD Phase II/Phase III Pipeline, 2016 211
  • Figure 11: Competitive Assessment of Late-Stage Pipeline Agents in MDD, 2015-2025 213
  • Figure 12: Clinical and Commercial Positioning of ALKS-5461 220
  • Figure 13: Clinical and Commercial Positioning of Vraylar 227
  • Figure 14: Clinical and Commercial Positioning of ASC-01 231
  • Figure 15: Clinical and Commercial Positioning of AXS-05 237
  • Figure 16: Clinical and Commercial Positioning of Esketamine 245
  • Figure 17: Clinical and Commercial Positioning of Rapastinel 253
  • Figure 18: Clinical and Commercial Positioning of Strada 260
  • Figure 19: Clinical and Commercial Positioning of Viotra 266
  • Figure 20: Company Portfolio Gap Analysis in MDD, 2015-2025 274
  • Figure 21: Global Sales by Region for MDD Therapies, 2015 and 2025 302
  • Figure 22: Global Sales by Region for MDD Therapies, 2015-2025 303
  • Figure 23: Global Sales by Drug Class for MDD Therapies, 2015 and 2025 304
  • Figure 24: Global Sales by Drug Class for MDD Therapies, 2015-2025 305
  • Figure 25: US Sales by Drug Class for MDD Therapies, 2015 and 2025 308
  • Figure 26: US Sales by Drug Class for MDD Therapies, 2015-2025 309
  • Figure 27: 5EU Sales by Drug Class for MDD Therapies, 2015 and 2025 312
  • Figure 28: 5EU Sales by Drug Class for MDD Therapies, 2015-2025 313
  • Figure 29: 5EU Sales by Region for MDD Therapies, 2015 and 2025 314
  • Figure 30: Japan Sales by Drug Class for MDD Therapies, 2015 and 2025 319
  • Figure 31: Japan Sales by Drug Class for MDD Therapies, 2015-2025 320
Back to Top